Spun out of Tübingen, Justus Liebig University Gießen and Münster, Atriva Therapeutics has raised an initial $1.4m to progress next-generation antiviral drugs for conditions including influenza.
Atriva Therapeutics, a Germany-based antiviral therapy spinout from the universities of Tübingen, Justus Liebig Gießen and Münster, has raised €1.3m ($1.4m) in an initial series A tranche co-led by public-private partnership High-Tech Gründerfonds and investment firm Meneldor. The round also features unnamed members of Atriva’s founding and management team. Founded in 2015, Atriva is working…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
